Cargando…

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application

Clinical trials of adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) to patients with advanced malignant melanoma have shown remarkable results with objective clinical responses in 50% of the treated patients. In order to initiate a clinical trial in melanoma, we have established...

Descripción completa

Detalles Bibliográficos
Autores principales:	Junker, Niels, thor Straten, Per, Andersen, Mads Hald, Svane, Inge Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135163/ https://www.ncbi.nlm.nih.gov/pubmed/21773037 http://dx.doi.org/10.1155/2011/574695

Ejemplares similares

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Therapeutic Cancer Vaccines in Combination with Conventional Therapy
por: Andersen, Mads Hald, et al.
Publicado: (2010)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot
por: Larsen, Stine Kiaer, et al.
Publicado: (2012)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

Cancer treatment: the combination of vaccination with other therapies
por: Andersen, Mads Hald, et al.
Publicado: (2008)

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
por: Iversen, Trine Zeeberg, et al.
Publicado: (2013)

A Potential Role of Indoleamine 2,3-Dioxygenase–Specific T cells in Leishmania Vaccination
por: Straten, Per thor, et al.
Publicado: (2011)

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
por: thor Straten, Per, et al.
Publicado: (2010)

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
por: Andersen, Rikke Sick, et al.
Publicado: (2010)

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
por: Sørensen, Rikke Bæk, et al.
Publicado: (2009)

Natural CD4(+) T-Cell Responses against Indoleamine 2,3-Dioxygenase
por: Munir, Shamaila, et al.
Publicado: (2012)

T-cell clonotypes in cancer
por: thor Straten, Per, et al.
Publicado: (2004)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
por: Andersen, Mads Hald, et al.
Publicado: (2006)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies
por: Knochelmann, Hannah M, et al.
Publicado: (2021)

Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers
por: Holmen Olofsson, Gitte, et al.
Publicado: (2014)

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes
por: Sittig, Simone P, et al.
Publicado: (2013)

Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses
por: Køllgaard, Tania, et al.
Publicado: (2012)

Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes
por: Køllgaard, Tania, et al.
Publicado: (2015)

Ex-vivo Clonally Expanded B Lymphocytes Infiltrating Colorectal Carcinoma Are of Mature Immunophenotype and Produce Functional IgG
por: Maletzki, Claudia, et al.
Publicado: (2012)

Characterization of T-cell responses against IκBα in cancer patients
por: Munir, Shamaila, et al.
Publicado: (2012)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas
por: Cordova, Adriana, et al.
Publicado: (2012)

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes
por: Håkansson, A, et al.
Publicado: (2001)

High frequency of T cells specific for cryptic epitopes in melanoma patients
por: Andersen, Rikke Sick, et al.
Publicado: (2013)

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2018)

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.
por: Håkansson, A., et al.
Publicado: (1996)

Collagen density regulates the activity of tumor-infiltrating T cells
por: Kuczek, Dorota E., et al.
Publicado: (2019)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ko1tsoe0o0bgdenohc972g787d